Dengue vaccine tetravalent - ICGEB/Sun Pharmaceutical Industries

Drug Profile

Dengue vaccine tetravalent - ICGEB/Sun Pharmaceutical Industries

Latest Information Update: 09 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator International Centre for Genetic Engineering and Biotechnology
  • Developer International Centre for Genetic Engineering and Biotechnology; Sun Pharmaceutical Industries
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 19 Oct 2016 Preclinical trials in Dengue in Italy (Parenteral) before October 2016
  • 19 Oct 2016 Dengue vaccine licensed to Sun Pharmaceutical Industries worldwide for the prevention of Dengue
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top